The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human DLL3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.

Disclosed are compositions of matter, protocols, and treatment means for inducing an enhanced immunity targeting tumor endothelium in order to prophylactically protect subjects from development of neoplasia. In one embodiment, the invention provides placental endothelial cells that are tissue culture expanded under proliferative conditions to resemble the tumor endothelial driven angiogenesis. The cells are subsequently treated with interferon gamma to increase immunogenicity and utilized as a prophylactic vaccine. Antibody and cell mediated immunity towards tumor endothelial associated antigens is quantified with the aim of establishing protective immunity which inhibits or blocks development of angiogenesis-dependent neoplasia.

The present disclosure relates generally to methods of treating or preventing cancer, the method comprising administering to a subject in need of treatment at least one tissue differentiation factor related polypeptide (TDFRP), wherein the TDFRP is administered in an amount effective to treat the cancer in the subject.